Insulin-Like Growth Factor Binding Protein 1 Predicts Insulin Sensitivity And Insulin Area-Under-The-Curve In Obese, Nondiabetic Adolescents

Lee, Phillip; Lustig, Robert H.; Lenders, Carine; Baillargeon, Jacques; Wilson, Darrell M.

doi:10.4158/ep15885.or

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The change in the proinsulin/insulin ratio from baseline was significantly different for all doses of TZP compared with placebo (p ≤ 0.016), and when using TZP at 10 and 15 mg compared with dulaglutide (p ≤ 0.007) at week 26 [25]. This study demonstrated that TZP improved insulin sensitivity as assessed by the HOMA2-IR index and circulating biomarkers associated with improved insulin sensitivity in response to diet, bariatric surgery, or weight loss (adiponectin, fasting IGF-binding proteins -IGFBP-1 and IGFBP-2) [27,28]. Insulin resistance as assessed by the HOMA2-IR index was significantly reduced in the 10 mg TZP-treated group compared with the placebo (p = 0.004) and dulaglutide-treated group (p = 0.004) at week 26.…”

Section: Phase 2 Clinical Trialsmentioning

confidence: 73%

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Nowak

Grzeszczak³

2022

Endokrynol Pol

View full text Add to dashboard Cite

intensively studied in clinical trials, showing not only hypoglycaemic effects but also influencing the comorbid metabolic components of the disease. These include the following: 1 -activin type II receptor modulators (bimagrumab), 2 -amylin or dual amylin-calcitonin receptor agonists (Pramlintide-amylin agonist), 3 -activator of adenosine monophosphate-activated protein kinase (AMPK) (A-769,662, thienopyridone), 4 -analogues of fibroblast growth factor 21 (pegbelfermin), 5 -fructose-1,6-bisphosphatase inhibitors (VK0612; MB07803), 6 -new GLP-1 receptor agonists (albiglutide, dulaglutide, exenatide, liraglutide, lyxisenatide, semaglutide, efpeglenatide, glutazumab, ITCA-650), 7 -drugs affecting the activity of the sodium-glucose cotransporter (SGLT 1 and 2) (SGLT 1 -licogliflozin, sotagliflozin and LX2761; SGLT 2 -kanagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, remogliflozin and tofogliflozin), or 8 -imeglimin belonging to a new group of drugs, so-called glimin [1,2].

show abstract

Section: Phase 2 Clinical Trialsmentioning

confidence: 73%

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Nowak

Grzeszczak³

2022

Endokrynol Pol

View full text Add to dashboard Cite

show abstract

Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up

Zhang

Dai²,

et al. 2018

OBES SURG

View full text Add to dashboard Cite

show abstract

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Thomas

Nikooienejad

Bray

et al. 2020

The Journal of Clinical Endocrinology &Amp; Metabolism

169

129

View full text Add to dashboard Cite

Context Novel dual GIP and GLP-1 receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide. Objective Explore mechanisms of glucose control by tirzepatide. Design Post-hoc analyses of fasting biomarkers and multiple linear regression analysis. Setting 47 sites in 4 countries. Patients or other Participants: 316 subjects with Type 2 diabetes. Interventions Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), placebo. Main Outcome Measures Analyze biomarkers of beta-cell function and insulin resistance (IR) and evaluate WL contributions to IR improvements at 26 weeks. Results HOMA2-B significantly increased with dulaglutide and tirzepatide 5, 10, and 15 mg compared with placebo (p<0.02). Proinsulin/insulin and proinsulin/C-peptide ratios significantly decreased with tirzepatide 10 and 15 mg compared with placebo and dulaglutide (p<0.007). Tirzepatide 10 and 15 mg significantly decreased fasting insulin (p<0.033) and tirzepatide 10 mg significantly decreased HOMA2-IR (p=0.004) compared with placebo and dulaglutide. Markers of improved insulin sensitivity (IS) adiponectin, IGFBP-1, and IGFBP-2 significantly increased by one or more doses of tirzepatide (p<0.05). To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and HbA1c was conducted. WL significantly (p<0.028) explained only 13% and 21% of improvement in HOMA2-IR with tirzepatide 10 and 15 mg, respectively. Conclusions Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control.

show abstract

Insulin-Like Growth Factor Binding Protein 1 Predicts Insulin Sensitivity And Insulin Area-Under-The-Curve In Obese, Nondiabetic Adolescents

Cited by 3 publications

References 23 publications

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Tirzepatide — a dual GIP/GLP-1 receptor agonist — a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes

Increased Serum IGFBP-1 and Reduced Insulin Resistance After Roux-En-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes: a 6-Month Follow-Up

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Contact Info

Product

Resources

About